India’s 1st CNS Tumor Methylation Classifier
Learn MoreWhat Is CNS Tumor Methylation Classifier?
A CNS Tumor Methylation Classifier is an advanced diagnostic tool that classifies central nervous system (CNS) tumors by analyzing DNA methylation patterns, an epigenetic modification where a methyl group is added to DNA, potentially silencing genes. These changes can lead to uncontrolled cell growth and cancer development. By identifying these unique methylation signatures, the classifier accurately determines the type and subtype of brain tumors, enabling more precise diagnosis and personalized treatment planning.
The World Health Organization’s 2021 CNS Tumor Classification has redefined how we diagnose brain tumors — combining histological and molecular insights to ensure accuracy.
Why the Classifier Matters
- Complements Conventional Histology
- Distinguishes Morphologically Similar Tumors
- Increases Diagnostic Specificity
- Resolves Diagnostic Discrepancies
- Identifies Novel Tumor Types
- Enables Accurate Tumor Subtyping for Better Prognosis
- Supports Personalized Treatment Planning
- Helps Avoid Unnecessary Therapies
- Facilitates Clinical Trial Enrolment
How it Works
- Platform: Whole Genome Methylation
- Technology: Captures methylation patterns across the entire genome
- Classification: Categorizes tumors into >90 classes
- Diagnostic Strength: >90% sensitivity and specificity
Test Details
- Test Code: MGM3615
- Test Name: CNS Tumor Methylation Classifier
- Sample Type: FFPE block (>30% tumor content), Fresh tissue*
- Turnaround Time: 21 Working Days
*Tumor cellularity for fresh tissue specimens should be pre-evaluated and mentioned in the Test Requisition Form (TRF)
Report Highlights:
- copy number variation (CNV) profiling
- confident molecular classification with calibrated scores
- WHO Grade assignment
Clinical Value & Impact
Precision Subtyping
e.g. Resolves histologically ambiguous cases and complex differentials (e.g., High grade neuroepithelial tumor (HGNET) vs Atypical teratoid/rhabdoid tumor (AT/RT).
Prognostic Clarity
e.g. WNT-activated medulloblastoma has a significantly better prognosis compared to SHH-activated or Group 3/4 variants.
Personalized Management
Enables treatment planning tailored to the tumor’s molecular profile — identifies resistance patterns and emerging targets.
Gene Coverage
IDH1, IDH2, H3-3A, MGMT, ATRX, TERTp, CDKN2A, CDKN2B, EGFR, GLI2, MET, MYB, MYBL1, MYCN, NF1, NF2, PDGFRA, PTCH1, PTEN, SMARCB1, TP53 … etc. Alterations in all chromosomes including 1p/19q co-deletion, chr7 gain/chr 10 loss, chr 14 alterations.
